Valve Thrombosis After TAVR: Larger-Diameter Valves and No Warfarin as Predictors

Valve Thrombosis After TAVRThere are limited data on the incidence, clinical implications, and predisposing factors of valve thrombosis in patients who underwent transcatheter aortic valve replacement (TAVR). This study aimed at determining such information through multislice computed tomography (CT).

 

This trial included 460 consecutive patients who underwent TAVR with a balloon-expandable Edwards Sapien XT or Sapien 3 (Edwards Lifesciences, Irvine, California) device.

 

Of those, 405 patients were assessed through multislice CT in addition to transthoracic or transesophageal echocardiography 1 to 3 months after TAVR. CT scans were evaluated for hypodense thickening matching valve thrombosis.

 

The CT confirmed signs of valve thrombosis in 28 patients (7%), 23 of which were completely asymptomatic. The remaining 5 patients presented symptoms indicating obstructive valve thrombosis.

 

Valve thrombosis risk did not differ among different generations of devices, but it was more frequent in patients who did not receive warfarin when compared with anticoagulated patients (10.7% vs. 1.8%; risk ratio [RR]: 6.09; 95% confidence interval [CI]: 1.86 to 19.84). Larger-diameter valves were associated with an increased risk of thrombosis (p = 0.03).

 

In a multivariable analysis, 29-mm devices (RR: 2.89; 95% CI: 1.44 to 5.80) and no post-TAVR warfarin treatment (RR: 5.46; 95% CI: 1.68 to 17.7) were independent predictors of thrombosis.

 

Treatment with warfarin effectively reverted valve thrombosis in 85% of patients, as shown by follow-up transesophageal echocardiography and multislice computed tomography.

 

Conclusion

Incidence of valve thrombosis after transcatheter aortic valve replacement in this study was 7%. Larger-diameter valves showed higher predisposition to thrombosis, whereas warfarin treatment had a protective effect. Although most patients did not present symptoms, the clinical implications of valve thrombosis may be important.

 

Original title: Transcatheter Aortic Valve Thrombosis Incidence, Predisposing Factors, and Clinical Implications.

Reference: Nicolaj C. Hansson et al. J Am Coll Cardiol. 2016;68(19):2059-2069.

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...